1aH-Dibenzo[b,f]oxireno[2,3-d]azepine-6(10bH)-carboxamide

Catalog No. :
ACSYXD430
CAS No. :
36507-30-9
Molecular Formula :
C15H12N2O2
Molecular Weight :
252.27

IUPAC Name:1a,10b-dihydro-6H-dibenzo[b,f]oxireno[2,3-d]azepine-6-carboxamide

1aH-Dibenzo[b,f]oxireno[2,3-d]azepine-6(10bH)-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$87.00Login to see priceIn stockInquiry
1g97%$234.00Login to see priceInquiryInquiry
5g97%$659.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1aH-Dibenzo[b,f]oxireno[2,3-d]azepine-6(10bH)-carboxamide
IUPAC Name1a,10b-dihydro-6H-dibenzo[b,f]oxireno[2,3-d]azepine-6-carboxamide
MDL No.MFCD00467137
Molecular FormulaC15H12N2O2
Molecular Weight252.27
SMILESNC(N1C2=CC=CC=C2C3OC3C4=CC=CC=C14)=O
InChI KeyZRWWEEVEIOGMMT-UHFFFAOYSA-N
Synonym1a,10b-Dihydro-6H-dibenz(b,f)oxiren(d)azepine-6-carboxamide | HY-W013378 | 6H-Dibenz[b,f]oxireno[d]azepine-6-carboxamide, 1a,10b-dihydro- | Carbamazepin-10,11-epoxide | MFCD00467137 | Q27106058 | SCHEMBL156675 | 1a,10b-Dihydro-6H-dibenz(b,f)oxireno(d)azep
CAS No.36507-30-9
PubChem CID2555

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACSYXD430 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCXWR082 route compound structure diagram
    ACCXWR082298-46-4 In Stock
  2. Then
  3. ACSYXD430 route product structure diagram
    ACSYXD43036507-30-9 In Stock
Inquiry

2. ACSYXD430 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACCXWR082 route compound structure diagram
    ACCXWR082298-46-4 In Stock
  4. Then
  5. ACSYXD430 route product structure diagram
    ACSYXD43036507-30-9 In Stock
Inquiry

Comments (0)